Analysis shows uveitis occurrence linked to improved survival in patients receiving combination therapy, suggesting systemic immune activation.
In 5966 patients treated with immune checkpoint inhibitors, uveitis was rare (0.49%) but linked to combination therapy, greater cumulative exposure, and prior uveitis. Uveitis occurrence was correlated with longer survival, suggesting heightened systemic immune activation.
No takes yet. Share an insight, caveat, or question.
Chew et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: